ABSTRACT
Assays of oestrogen receptors in either primary or metastatic disease provide useful information on the likelihood of response to endocrine therapy in patients with advanced breast cancer. Thus, response to therapy is largely restricted to patients who have tumours with substantial levels of oestrogen receptors; conversely, women having tumours without receptors have little chance of responding to endocrine manipulations and should be treated with other therapeutic modalities.
